LENZ Therapeutics (LENZ) Competitors $29.52 +0.64 (+2.22%) Closing price 04:00 PM EasternExtended Trading$29.51 -0.01 (-0.03%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. XENE, MLTX, ALVO, IMVT, HCM, ACAD, APLS, AMRX, RXRX, and IBRXShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Immunovant (IMVT), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Xenon Pharmaceuticals MoonLake Immunotherapeutics Alvotech Immunovant HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Xenon Pharmaceuticals (NASDAQ:XENE) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Does the MarketBeat Community believe in XENE or LENZ? Xenon Pharmaceuticals received 410 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 69.74% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes42469.74% Underperform Votes18430.26% LENZ TherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes Which has higher valuation and earnings, XENE or LENZ? LENZ Therapeutics has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M310.72-$182.39M-$3.02-12.68LENZ TherapeuticsN/AN/A-$124.65M-$4.77-6.19 Which has more risk and volatility, XENE or LENZ? Xenon Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Do analysts recommend XENE or LENZ? Xenon Pharmaceuticals presently has a consensus price target of $56.78, suggesting a potential upside of 48.32%. LENZ Therapeutics has a consensus price target of $46.60, suggesting a potential upside of 57.86%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is XENE or LENZ more profitable? Xenon Pharmaceuticals' return on equity of -24.69% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% LENZ Therapeutics N/A -58.48%-55.50% Does the media favor XENE or LENZ? In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than LENZ Therapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.43 beat Xenon Pharmaceuticals' score of 1.08 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in XENE or LENZ? 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryXenon Pharmaceuticals beats LENZ Therapeutics on 9 of the 17 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$813.07M$2.97B$5.55B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-6.1930.5222.6818.83Price / SalesN/A494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book1.343.216.794.33Net Income-$124.65M-$72.35M$3.22B$247.97M7 Day Performance9.86%3.75%2.44%2.71%1 Month Performance15.72%7.34%3.78%3.37%1 Year Performance79.89%-22.52%17.05%5.80% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.9923 of 5 stars$29.52+2.2%$46.60+57.9%+82.7%$813.07MN/A-6.19110News CoverageXENEXenon Pharmaceuticals2.589 of 5 stars$34.70-1.2%$56.78+63.6%-10.4%$2.66B$9.43M-12.30210Upcoming EarningsOptions VolumeNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.5442 of 5 stars$40.00+4.4%$80.50+101.3%-3.3%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastPositive NewsALVOAlvotech1.9667 of 5 stars$8.33+0.5%$18.00+116.1%-45.2%$2.51B$489.68M-4.504Short Interest ↑News CoverageIMVTImmunovant2.2463 of 5 stars$14.46-4.6%$41.00+183.5%-44.2%$2.46BN/A-5.52120Gap DownHigh Trading VolumeHCMHUTCHMED1.9651 of 5 stars$13.89+0.9%$19.00+36.8%-21.1%$2.42B$630.20M0.001,760Upcoming EarningsShort Interest ↑ACADACADIA Pharmaceuticals4.2723 of 5 stars$14.38-2.4%$23.93+66.4%-14.5%$2.40B$957.80M18.44510Upcoming EarningsAPLSApellis Pharmaceuticals4.1548 of 5 stars$18.03-0.9%$45.35+151.5%-56.4%$2.26B$781.37M-8.88770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageAMRXAmneal Pharmaceuticals3.3893 of 5 stars$7.13-3.1%$10.80+51.5%+26.5%$2.21B$2.79B-10.497,600Earnings ReportNews CoveragePositive NewsRXRXRecursion Pharmaceuticals2.2741 of 5 stars$5.41-1.6%$8.20+51.6%-34.1%$2.17B$58.49M-3.54400Upcoming EarningsGap UpIBRXImmunityBio1.613 of 5 stars$2.51+1.6%$12.19+385.6%-70.8%$2.14B$14.75M-2.73590Upcoming EarningsGap Up Related Companies and Tools Related Companies XENE Competitors MLTX Competitors ALVO Competitors IMVT Competitors HCM Competitors ACAD Competitors APLS Competitors AMRX Competitors RXRX Competitors IBRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
